BioMap Unveils 11 AI Life-Science Deals at Hong Kong Summit

BioMap announced collaborations with 11 partners at the International Bio-Computing Innovation Summit 2026 in Hong Kong, pushing its AI foundation models into drug research, traditional Chinese medicine, agricultural breeding and overseas expansion.

The summit opened at the Hong Kong Convention and Exhibition Centre on November 6, 2026. Seven projects were presented at a morning launch ceremony for BioMap InnoHub. Four more organizations joined at an afternoon ceremony. BioMap hosted the event with support from Hong Kong Investment Corporation Limited.

The stated goal is twofold: advance AI research and applications in life sciences, and accelerate commercialization of research outcomes in Hong Kong.

What does the medical research cover?

The University of Hong Kong project advances the next phase of the Breast Cancer Virtual Cell Large Model, using AI to simulate breast-cancer cell functioning. HKIC CEO Clara Chan said in her November 6 summit speech that the breast-cancer model's phase II was launching in 2026, after an earlier multimodal breast-cancer tumor-cell foundation model was released at the 2025 summit.

Two other morning projects target therapeutics:

• BioMap and Hong Kong Baptist University will establish an AI Traditional Chinese Medicine Joint Laboratory, combining computational analysis with experimental validation to investigate how traditional Chinese medicine ingredients work.
• A Novel Peptide Drug Incubation initiative with PepLib aims to accelerate research and development of peptide and cyclic peptide therapeutics.

How far does the portfolio reach beyond medicine?

Agriculture received a parallel push. BioMap and Soy-Sky FarmTech will combine biological foundation models with crop genetic and trait data in an AI Breeding Platform designed to support breeding decisions. The partners also plan a Belt and Road AI Agricultural Innovation Ecosystem.

Separately, BioMap will work with DEFTA Partners on the DEFTA Overseas Market Expansion Program, exploring research and industry collaboration in Japan and other overseas markets.

What infrastructure is being built?

Several collaborations concentrate on connecting models with experiments. BioMap's initiative with Coyote Bioscience combines research translation across industry, academia and research institutions with an open cartridge ecosystem, and supports collaboration on molecular point-of-care testing in Hong Kong.

Its work with HiDream.ai on a Cross-Scale Virtual Organism Model will study biological phenomena at different scales and explore ways to predict and reconstruct their dynamics.

The afternoon ceremony added two planned facilities:

• Temasek Life Sciences Laboratory: BioMap will work with the Singapore-based institute on plans to jointly establish an AI Bio-Computing Center in Singapore. The center remains at the planning stage.
• Revvity: a planned AI biomanufacturing laboratory integrating computational and experimental workflows in a closed loop.

What is MegaStream TechBio?

The afternoon program also featured MegaStream TechBio, the drug-development venture jointly established by BioMap and Harbour BioMed. CEO Kyler Lei made his first public appearance, outlined a drug-discovery vision called AIDD 3.0 and discussed a pipeline organized around First-in-Class and Best-in-Class programs.

The presentation built on a partnership disclosed earlier in the year. Harbour BioMed's June 15, 2026 announcement said the companies would launch MegaStream as an AI-native pipeline company targeting global markets.

Under that plan, Harbour BioMed would contribute its fully human antibody platform, target-biology expertise and global clinical-development capabilities. BioMap would supply foundational AI technology, model engineering and intelligent research-and-development capabilities.

MegaStream's initial pipeline was to combine candidates identified by AI in the partners' earlier collaborations with newly launched AI-driven discovery programs, prioritizing complex biologics across cardiovascular, renal, oncology and anti-aging areas.

The June release also described a planned dry-wet discovery laboratory linking computational design with experimental validation. Harbour BioMed projected efficiency gains above 500% over previous-generation platforms, a more than tenfold increase in data-accumulation efficiency and over 5 petabytes of AI-ready life-science data within five years. Those figures are operating targets for the planned laboratory, not performance results announced at the November summit.

For BioMap, the execution test is whether this expanding network can turn model predictions and automated experiments into validated therapies, breeding tools and commercial research outcomes across the regions covered by the summit partnerships.